Treatment of the case of pure red cell aplasia - A description;Opis przypadku leczenia wybiorczej aplazji czerwonokrwinkowej

Polskie Archiwum Medycyny Wewnetrznej

Volumn 98, Issue 3, 1997, Pages 231-234

  Giedrojć, Jan ^a   Janczarek, Barbara ^a   Klimuk, Marzenna Beata ^a   Płonowski, Andrzej ^a   Bielawiec, Michał ^a  

^a Klinika Hematologii   (Poland)

Author keywords

Immunosuppressive therapy; Monoclonal antibody OKT3 of IgG2a type; Pure red cell aplasia; Thymoglobuline

Indexed keywords

HYDROCORTISONE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; OKT 3; STEROID; THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY;

ADULT; ARTICLE; CASE REPORT; ERYTHROCYTE APLASIA; HEMATOLOGIC DISEASE; HEMATOLOGICAL PARAMETERS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; SERUM SICKNESS; SYMPTOMATOLOGY; TREATMENT OUTCOME; PURE RED CELL ANEMIA;

ADULT; ANTILYMPHOCYTE SERUM; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; MALE; RED-CELL APLASIA, PURE;

EID: 0031219216     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Baldus M., Moller M., Walter H., Brass H., Queisser W.: A case of pure red cell aplasia: follow-up on different immunosupressive regimens. Clin. Investig., 1994, 72, 1051.
2. Adamczyk-Cioch M.B., Dmoszyńska A., Hus I., Legieć W., Jawniak D.: Leczenie rekombinowana ludzka erytropoetyna (rHuEPO) wybiórczej aplazji czerwonokrwinkowej w nastepstwie terapii 2-chlorodeoksyadenozyna chorej na przewlekła białaczke limfatyczna - opis przypadku. Acta Haematol Pol., 1996, 27, 193.
3. Azai K., Kitejima H., Kubo M.: A case of pure red cell aplasia associated with sodium valproate therapy. Rinscho-Ketsueki, 1994, 35, 286.
4. Gotte M., Basara N., Rolovic Z. i wsp.: Successful treatment of refractory pure red cell aplasia secondary to chronic lymphocytic laeukemia with cyclosporine A: correlation between clinical and in vitro effects. Nouv. Rev. Fr. Hematol., 1994, 36, 307.
5. Sakai S., Shimabukuro K., Murakami E., Iwato S., Fuwa S., Hirose H.. A case on invasive thymoma with myasthenia gravis and pure red cell aplasia. Nippon Kyobu Gakkai Zasshi, 1995, 43, 60.
6. Dessypris E.N.: The biology of pure red cell aplasia. Semin. Hematol., 1991, 28, 275.
7. Freud L.G., Hippe E., Strandgrad S., Ersley A.J.: Complete remission in pure red cell aplasia after plasmapheresis. Scand. J. Haematol., 1985, 35, 315.
8. Kohler G., Milstein C.. Continuous cultures of fused cells secretin antibody of predefined specyficity. Nature, 1975, 256, 395.
9. Goldstein G. Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation. Transplantation proceedings, 1987, 29, suppl. 1, 1.
10. Abramowicz D , Goldman M., De Paw L., Vanherweghem J.I.: The long term effects of prophylactic OKT3 monoclonal antibody in cadaver kidney transplantation - A single center, prospective, randomized study. Transplantation, 1992, 54, 443.
11. Norman D.J.: The clinical role of OKT3. Cardiology Clinics, 1990, 8, 97.
12. Norman D.J., Kahana L., Stuart P.P. i wsp.: Transplantation, 1993, 55, 44.
13. Oh C.S , Stratta R.J., Fox B.C., Sollinger H.W.: Increased infections associated with the use of OKT3 for treatment of steroid - resistant rejection on renal transplantation. Transplantation, 1988, 45, 68.